Back to search
T-lymphoblastic Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which T-lymphoblastic Lymphoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which T-lymphoblastic Lymphoma trials you may qualify forBackground: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a…
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the c…
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-r…
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who ach…
This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric…
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, a…
To evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation as consolidation therapy in…
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treat…